Previous 10 | Next 10 |
- Joe Kelly has been appointed to the newly created role of Head of U.S. Commercial, Endocrinology - Scott A. Holmes has been appointed to the newly created role of Head of Global Commercial Strategy, Endocrinology - Jesper Høiland, Global Chief Comm...
Ascendis Pharma (ASND) and Visen Pharmaceuticals' lonapegsomatropin (TransCon hGH) showed to be better than a daily human growth hormone (hGH) in a phase 3 trial in children with growth hormone deficiency (GHD) in China. "The trial met its primary objective, demonstrating that lonap...
Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended March 31, 2022, Baron Health Care Fund (the “Fund”) declined 9.93% (Institutional Shar...
Ascendis Pharma (ASND) stock fell ~5% on May 12 after five firms lowered their price target on the stock following Q1 results. Wells Fargo cut its price target on ASND to $176 from $190. Analyst Derek Archila kept an Overweight rating on the stock and noted that Q1 revenue of growth...
Ascendis Pharma (ASND -4.2%) fell sharply likely in reaction to Dovish biotech's earnings report that got the Wall Street's analysts off the ground to lower their price target over SKYTROFA cautious outlook. The company's SKYTROFA is a FDA-approved once-weekly inject...
Shares of Ascendis Pharma (NASDAQ: ASND) were down by 10.5% as of 12:10 p.m. ET Thursday. The decline came after the drugmaker announced its first-quarter results following the market close on Wednesday. The Denmark-based multinational reported Q1 revenue of 6.8 million euros, a...
Gainers: Cullinan Oncology (CGEM) +21%. Concert Pharmaceuticals (CNCE) +20%. Babylon Holdings BBLN +16%. Blue Water Vaccines (BWV) +14%. ViewRay (VRAY) +10%. Losers: Eargo (EAR) -24%. Senseonics (SENS) -14%. Ascendis Pharma (ASND) -11%. Evaxion Biotech...
Ascendis Pharma A/S (ASND) Q1 2022 Earnings Conference Call May 11, 2022, 4:30 PM ET Company Participants Jan Mikkelsen – President and Chief Executive Officer Scott T. Smith – Senior Vice President and Chief Financial Officer Timothy J. Lee – Senior Director of Investmen...
Ascendis Pharma press release (ASND): Q1 GAAP EPS of -€2.21 misses by €0.05. Revenue of €6.83M (+875.7% Y/Y) beats by €1.98M. For further details see: Ascendis Pharma GAAP EPS of -€2.21 misses by €0.05, revenue of €6.83M beats b...
Phase 3 PaTHway Trial top-line results demonstrated potential of TransCon™ PTH to become the first parathyroid replacement therapy for adults with hypoparathyroidism TransCon PTH U.S. FDA regulatory submission on track for Q3 and EU MAA for Q4 2022 Increasing up...
News, Short Squeeze, Breakout and More Instantly...
2024-04-19 17:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 15 years by 17.87% on an annualized basis producing an average annual retur...
Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 44.46% on an annualized basis producing an average annual retur...